226 completed, 47 unknown, 18 terminated, 17 recruiting. 133 Phase 4, 93 Phase 3, 38 Phase 1, 37 Phase 2, 26 Not applicable.
Follow Valsartan: new trials by email Literature Review of Valsartan trials Research Report on Valsartan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients Metformin, Val, Cel and Met XR Low, Val, Cel and Met XR High - Type 2 Diabetes, High Blood Pressure | Phase 1 / Phase 2 | Withdrawn | ARKAY Therapeutics | 2026-12-10 | 2026-07-16 | |
| Sacubitril/Valsartan Versus Valsartan Alone on Left Atrial Volume Index in Hypertensive Patients Sacubitril / Valsartan, Valsartan - Hypertension, Left Ventricular Diastolic Dysfunction | Not applicable | Not yet recruiting | University of Health Sciences Lahore | 102 | 2026-10-01 | 2026-10-02 |
| TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy Metformin XR, Celecoxib, Valsartan - Type 2 Diabetes (T2DM) | Phase 2 | Not yet recruiting | Myopharm Limited | 48 | 2026-09-01 | 2026-07-08 |
| Neprilysin Inhibition to Reduce Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction Sacubitril-valsartan, Valsartan - Heart Failure With Preserved Ejection Fraction, Myocardial Fibrosis | Phase 4 | Withdrawn | Brigham and Women's Hospital | 2026-08-27 | 2026-08-31 | |
| Effects of VALsartan On atRIAl Mitral Regurgitation (VALORIA) - Pilot Valsartan, Placebo - Atrial Functional Mitral Regurgitation | Phase 2 / Phase 3 | Recruiting | Jonathan Beaudoin | 50 | 2026-07-13 | 2026-08-20 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control Exforge HCT® or Three Individual drug amlodipine + valsartan + hydrochlorothiazide - Intracerebral Hemorrhage | Not applicable | Recruiting | The University of Hong Kong | 140 | 2026-03-01 | 2026-03-09 |
| Effectiveness of Valsartan Alone vs Combination Therapy in Hypertensive Heart Disease Valsartan + Hydrochlorothiazide - Heart Diseases, Hypertension | Phase 1 | Completed | Shaikh Zayed Hospital, Lahore | 118 | 2025-11-01 | 2026-04-22 |
| A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin Metformin, Empagliflozin, Midazolam - Overweight Subject, Healthy Subjects | Phase 1 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 111 | 2025-09-24 | 2026-01-09 |
| Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy Bisoprolol, Valsartan, sacubitril/ valsartan - Takotsubo Cardiomyopathy | Not applicable | Recruiting | University of Edinburgh | 100 | 2025-08-08 | 2026-09-18 |
| Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin), Colchicine 0.5 mg, Usual Care Group - Atherothrombotic Diseases, Atherosclerotic Cardiovascular Disease (ASCVD) | Phase 3 | Recruiting | Hospital do Coracao | 7713 | 2025-06-12 | 2026-01-22 |
| A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents Valsartan Oral Solution, Placebo - Essential Hypertension | Phase 3 | Enrolling by invitation | Shandong New Time Pharmaceutical Co., LTD | 342 | 2025-02-05 | 2025-03-07 |
| A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients SYH9056, Levamlodipine, Valsartan - Mild-to-moderate Essential Hypertension | Phase 3 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 606 | 2025-01-24 | 2025-01-13 |
| ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling Sacubitril/Valsartan 49 MG-51 MG Oral Tablet [ENTRESTO], Empagliflozin10Mg Tab - Heart Failure | Not applicable | Completed | Rehab Werida | 180 | 2025-01-01 | 2026-06-02 |
| QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension QR12000 75mg, QR12000 75mg placebo, QR12000 150mg - Essential Hypertension | Phase 3 | Not yet recruiting | Wuhan Createrna Science and Technology Co., Ltd | 810 | 2024-12-30 | 2024-12-06 |
| Cardiac Left Atrial Evaluation and Response in HFrEF With Sacubitril/Valsartan Sacubtril/Valsartan - Heart Failure and Reduced Ejection Fraction | Completed | Connolly Hospital Blanchardstown | 334 | 2024-11-01 | 2026-04-13 | |
| Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A Sacubitril∙Valsartan(dose maintenance), Sacubitril∙Valsartan(dose increasing), Valsartan - Essential Hypertension | Phase 3 | Recruiting | Chong Kun Dang Pharmaceutical | 324 | 2024-10-14 | 2025-12-11 |
| Clinical Response of EXTOR (Amlodipine/Valsartan) in Newly Diagnosed Hypertensive Patients. Fixed-Dose Combination of Amlodipine/Valsartan - Hypertension | Recruiting | The Searle Company Limited Pakistan | 420 | 2024-09-28 | 2025-05-15 | |
| Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy Sacubitril/Valsartan, Valsartan - Essential Hypertension, Type 2 Diabetes | Phase 4 | Unknown | Sichuan Academy of Medical Sciences | 297 | 2024-08-01 | 2024-07-15 |
| Bioequivalence Study of Amlodipine/Valsartan 10/160 mg Film Coated Tablets Amlodipine/Valsartan, Amlodipine 10 mg &valsartan 160 mg (Exforge) - Healthy Volunteer | Phase 1 | Unknown | International Bio service | 48 | 2024-05-07 | 2024-01-09 |
Showing 20 of 330. Sign in to see all of them.
Hypertension (165) · Heart Failure (34) · Diabetes Mellitus, Type 2 (22) · Essential Hypertension (22) · Cardiovascular Diseases (15) · Diabetes Mellitus (12) · Renal Insufficiency, Chronic (11) · Hypertrophy, Left Ventricular (9) · Stroke (7) · COVID-19 (6) · Diabetic Nephropathies (6) · Heart Failure, Systolic (6) · Hypercholesterolemia (6) · Hyperlipidemias (6) · Kidney Diseases (6)
Novartis (65) · Novartis Pharmaceuticals (40) · Boehringer Ingelheim (6) · Boryung Pharmaceutical Co., Ltd (4) · Damanhour University (4) · HK inno.N Corporation (4) · JW Pharmaceutical (4) · LG Life Sciences (4) · Asan Medical Center (3) · AstraZeneca (3) · Bayer (3) · Brigham and Women's Hospital (3) · Guangdong Provincial People's Hospital (3) · Hanlim Pharm. Co., Ltd. (3) · IlDong Pharmaceutical Co Ltd (3)
United States (90) · South Korea (41) · Germany (40) · China (36) · Switzerland (30) · France (26) · Italy (24) · Spain (22) · Japan (20) · Canada (19) · India (17) · Poland (17) · Netherlands (16) · Brazil (15) · Hungary (15)
Nancy J Brown, MD (3) · Ariya Khunvichai, Ph.D (2) · Duk-Hyun Kang, M.D. (2) · Eugene Braunwald, MD (2) · KyoungSook Kim, PhD (2) · Kyun Seop Bae, MD (2) · Pankaj Arora, MD, FAHA (2)
PMID 38682786, PMID 20228403, PMID 26280447, PMID 29754651, PMID 32905623, PMID 35115085, PMID 36398903, PMID 37401523, PMID 38299639, PMID 10639539, PMID 11500748, PMID 11897754, PMID 11937179, PMID 12135313, PMID 12493255, PMID 14581662, PMID 14656957, PMID 15207952, PMID 15367828, PMID 15879332, PMID 16448896, PMID 16476843, PMID 17179034, PMID 17253471, PMID 17337887, PMID 17389264, PMID 17467513, PMID 17485598, PMID 17510503, PMID 17586303, PMID 17922981, PMID 18268136, PMID 18326958, PMID 18343247, PMID 18498915, PMID 18538118, PMID 18539917, PMID 18591457, PMID 18593517, PMID 18653268, PMID 18698222, PMID 18716365, PMID 18761785, PMID 18776118, PMID 18926145, PMID 19014834, PMID 19120715, PMID 19196360, PMID 19300114, PMID 19410718
2016 (4), 2009 (2), 2015 (2), 2023 (2), R01HL065193 (2), 2004 (1), 2017 (1), 2019 (1), K23DK117041 (1), K23HL168163 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1)